Later this week, Nicolas Geades, Imaging Director at Antaros Medical, will be speaking at the Innovation in Obesity Therapeutics Summit. His talk ‘Underneath the lost kilos: imaging in obesity and metabolic disease drug development’ will explore how body and muscle composition and organ-related insights captured with imaging provide deeper understanding of treatment effects in clinical trials.
More specifically, the talk will cover:
- Imaging methodologies like magnetic resonance imaging (MRI) and dual-energy x-ray absorptiometry (DXA or DEXA) provide information about different aspects of body composition meeting different needs in clinical trials
- MRI-based methods can also provide detailed insights into muscle composition including inter- and intramuscular adipose tissue as well as intramyocellular lipids.
- Body- and muscle composition assessment can be combined with measures of other end-organ effects and function for a deeper understanding of treatment responses
Join us at the West Coast Innovation in Obesity Therapeutics Summit in San Diego, December 2–4. Don’t miss Nicolas’ session on Wednesday, December 3 at 3:10 PM PST.
Why imaging matters in obesity drug development
Obesity and metabolic diseases are multifactorial conditions with complex pathophysiology. As drug development in this space accelerates, there is a growing need for tools that can provide deeper insights into treatment effects beyond traditional endpoints like weight loss. Imaging can help by revealing the source of weight loss, such as changes in lean tissue or fat redistribution, as well as capturing effects on other metabolically linked organs including the liver, kidney and heart. These insights are important for understanding mechanisms of action and demonstrating broader therapeutic benefits in an increasingly competitive market.